Key result
VBX bridging stent in BEVAR achieves ~98% 1-year primary patency.
Why the study?
Bridging stent stability is critical for the effectiveness and safety of BEVAR for complex abdominal and thoracoabdominal aortic aneurysms, yet multicenter real-world data on the clinical performance and safety of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis as a bridging stent remain limited.
Does the GORE VIABAHN VBX Balloon Expandable Endoprosthesis maintain patient-level primary patency at 12 months when used as a bridging stent during BEVAR in patients with complex abdominal and thoracoabdominal aortic aneurysms?
Cohort (n=165)
Yes
Does the GORE VIABAHN VBX Balloon Expandable Endoprosthesis maintain patient-level primary patency at 12 months when used as a bridging stent during BEVAR in patients with complex abdominal and thoracoabdominal aortic aneurysms?
In a multicenter European registry of 165 patients undergoing BEVAR for complex and thoracoabdominal aortic aneurysms, the GORE VIABAHN VBX bridging stent graft demonstrated 99.6% technical success and 97.7% patient-level primary patency at 1 year.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Having an FDA-approved bridging stent option specifically indicated for these procedures and backed by longer-term clinical evidence is an important advancement for physicians treating these challenging cases and, ultimately, for the patients who may benefit from these procedures.”
“Alongside the expanded U.S. indication for the VBX Stent Graft, these three-year EMBRACE Registry outcomes add important longer-term evidence in complex aortic care. We will continue sharing real-world results as follow-up progresses, giving physicians a clearer picture of the longer-term performance of the VBX Stent Graft in FEVAR and BEVAR.”
Supports VBX bridging in BEVAR; extends multicenter registry data but leaves open randomized confirmation of durability.
Objective: The stability of bridging stents is critical to ensure the effectiveness and safety of branched endovascular aortic repair (BEVAR) for complex and thoracoabdominal aortic aneurysms (TAAA). The goal of this multicenter registry was to assess the clinical performance and safety of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) as a bridging stent in BEVAR. Methods: The EMBRACE registry is a multicenter study across 14 European centers with retrospective enrollment and prospective follow-up. Patients were divided into BEVAR and fenestrated endovascular aneurysm repair (FEVAR) arms. This analysis reports the BEVAR cohort, which included patients receiving the VBX Stent Graft as a bridging stent for at least 1 visceral vessel. The primary endpoint was patient-level primary patency at 12 months. Secondary endpoints included technical success, reintervention, and target vessel patency assessed annually for up to 5 years. Secondary safety outcomes included major adverse events and aneurysm-related mortality. Results: A total of 165 patients (69.1% male, mean age 72.5 ± 9 years) were enrolled, receiving 454 VBX Stent Grafts (26.0% celiac trunk, 28.9% superior mesenteric artery (SMA), 21.8% left renal, and 23.3% right renal artery). VBX Stent Graft technical success was 99.6%. Thirty-day mortality was 7.9%, with major adverse events in 15.2% (1.8% respiratory failure, 7.3% renal function deterioration, 0.6% bowel ischemia, 4.2% paraplegia, and 1.8% major stroke). Freedom from aneurysm-related mortality was 92.1% at 30 days and 90.2% at 1 year. Freedom from patient-level VBX-related reintervention was 91.7%. Patient-level primary patency and secondary patency were 97.7% and 98.5%, respectively. Freedom from target vessel instability at the patient level was 90.4%. Conclusion: Short-term findings from this multicenter registry confirm that the VBX Stent Graft is a safe and effective bridging stent for BEVAR, demonstrating high technical success, excellent 1-year patency, and low rates of target vessel instability. Ongoing follow-up will evaluate mid-term durability. Clinical Impact Bridging stent performance is fundamental to the success of branched endovascular repair, yet multicenter, real-world data remain limited. This analysis from the EMBRACE registry demonstrates high technical reliability, excellent 1-year target vessel patency, and low rates of VBX Stent Graft-related reintervention. Technical failures were uncommon and were primarily associated with inadequate distal landing zones, highlighting the importance of procedural planning. These findings provide clinicians with contemporary evidence supporting the VBX Stent Graft as a safe and effective bridging stent for BEVAR and may inform procedural decision-making to optimize target vessel durability.
No takes yet. Share an insight, caveat, or question.
Bertoglio et al. (2026) conducted a cohort in Complex abdominal and thoracoabdominal aortic aneurysms (TAAA) treated with branched endovascular aortic repair (BEVAR) (n=165). GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) as a bridging stent in BEVAR was evaluated on Patient-level primary patency at 12 months. The GORE VIABAHN VBX bridging stent in BEVAR achieved 97.7% patient-level primary patency, 98.5% secondary patency, and 91.7% freedom from VBX-related reintervention at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: